共 47 条
[1]
Criss SD(2019)Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States Urol Oncol 37 180e111-180e118
[2]
Weaver DT(2015)Global cancer statistics, 2012 CA Cancer J Clin 65 87-108
[3]
Sheehan DF(2020)Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma N Engl J Med 383 1218-1230
[4]
Torre LA(2019)Immune checkpoint inhibitors as switch or continuation maintenance therapy in solid tumors: rationale and current state Target Oncol 14 505-525
[5]
Bray F(2012)Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves BMC Med Res Methodol 12 9-45
[6]
Siegel RL(2020)United States life tables, 2018 Natl Vital Stat Rep 69 1-e30
[7]
Ferlay J(2021)Cost-effectiveness of pembrolizumab versus carboplatin-based chemotherapy as first-line treatment of PD-L1-positive locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-based therapy in the United States Clin Genitourin Cancer 19 e17-1177
[8]
Lortet-Tieulent J(2014)Cost-effectiveness of neoadjuvant chemotherapy before radical cystectomy for muscle-invasive bladder cancer Urol Oncol 32 1172-571
[9]
Jemal A(2019)Cost-effectiveness of pembrolizumab for patients with advanced, unresectable, or metastatic urothelial cancer ineligible for cisplatin-based therapy Eur Urol Oncol 2 565-1103
[10]
Powles T(2016)Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine JAMA 316 1093-406